Cidofovir

Last updated
Cidofovir
Cidofovir.svg
Clinical data
Trade names Vistide
AHFS/Drugs.com Monograph
Pregnancy
category
  • AU:D
Routes of
administration 		Intravenous
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability complete
Protein binding <6%
Elimination half-life 2.6 hours (active metabolites: 15–65 hours)
Excretion renal The above pharmacokinetic parameters are measured for cidofovir used in conjunction with probenecid. [3]
Identifiers
  • ({[(S)-1-(4-amino-2-oxo-1,2-dihydropyrimidin-1-yl)-3-hydroxypropan-2-yl]oxy}methyl)phosphonic acid
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
NIAID ChemDB
CompTox Dashboard (EPA)
ECHA InfoCard 100.166.433 OOjs UI icon edit-ltr-progressive.svg
Chemical and physical data
Formula C8H14N3O6P
Molar mass 279.189 g·mol−1
3D model (JSmol)
Specific rotation -97.3
Melting point 260 °C (500 °F)
  • O=C1/N=C(\C=C/N1C[C@H](OCP(=O)(O)O)CO)N
  • InChI=1S/C8H14N3O6P/c9-7-1-2-11(8(13)10-7)3-6(4-12)17-5-18(14,15)16/h1-2,6,12H,3-5H2,(H2,9,10,13)(H2,14,15,16)/t6-/m0/s1 Yes check.svgY
  • Key:VWFCHDSQECPREK-LURJTMIESA-N Yes check.svgY
   (verify)

Cidofovir, brand name Vistide, is a topical or injectable antiviral medication primarily used as a treatment for cytomegalovirus (CMV) retinitis (an infection of the retina of the eye) in people with AIDS. [4] [5]

Contents

Cidofovir was approved for medical use in 1996. [6]

Medical use

DNA virus

Its only indication that has received regulatory approval worldwide is cytomegalovirus retinitis. [4] [5] Cidofovir has also shown efficacy in the treatment of aciclovir-resistant HSV infections. [7] Cidofovir has also been investigated as a treatment for progressive multifocal leukoencephalopathy with successful case reports of its use. [8] Despite this, the drug failed to demonstrate any efficacy in controlled studies. [9] Cidofovir might have anti-smallpox efficacy and might be used on a limited basis in the event of a bioterror incident involving smallpox cases. [10] Brincidofovir, a cidofovir derivative with much higher activity against smallpox that can be taken orally has been developed. [11] It has inhibitory effects on varicella-zoster virus replication in vitro although no clinical trials have been done to date, likely due to the abundance of safer alternatives such as aciclovir. [12] Cidofovir shows anti-BK virus activity in a subgroup of transplant recipients. [13] Cidofovir is being investigated as a complementary intralesional therapy against papillomatosis caused by HPV. [14] [15]

It first received FDA approval on 26 June 1996, [16] TGA approval on 30 April 1998 [5] and EMA approval on 23 April 1997. [17]

It has been used topically to treat warts. [18]

Other

It has been suggested as an antitumour agent, due to its suppression of FGF2. [19] [20] [21]

Administration

Cidofovir is only available as an intravenous formulation. Cidofovir is to be administered with probenecid which decreases side effects to the kidney. [22] Probenecid mitigates nephrotoxicity by inhibiting organic anion transport of the proximal tubule epithelial cells of the kidney. [23] In addition, hydration must be administered to patients receiving cidofovir. 1 liter of normal saline is recommended in conjunction with each dose of cidofovir. [22]

Side effects

The major dose-limiting side effect of cidofovir is nephrotoxicity (i.e., kidney damage). [24] Other common side effects (occurring in >1% of people treated with the drug) include: [4] [24]

Whereas uncommon side effects include: anaemia and elevated liver enzymes and rare side effects include: tachycardia and Fanconi syndrome. [24] Probenecid (a uricosuric drug) and intravenous saline should always be administered with each cidofovir infusion to prevent this nephrotoxicity. [25]

Contraindications

Hypersensitivity to cidofovir or probenecid (as probenecid needs to be given concurrently to avoid nephrotoxicity). [4]

Interactions

It is known to interact with nephrotoxic agents (e.g. amphotericin B, foscarnet, IV aminoglycosides, IV pentamide, vancomycin, tacrolimus, non-steroid anti-inflammatory drugs, etc.) to increase their nephrotoxic potential. [4] [5] As it must be given concurrently with probenecid it is advised that drugs that are known to interact with probenecid (e.g. drugs that probenecid interferes with the renal tubular secretion of, such as paracetamol, aciclovir, aminosalicylic acid, etc.) are also withheld. [5]

Mechanism of action

Its active metabolite, cidofovir diphosphate, inhibits viral replication by selectively inhibiting viral DNA polymerases. [5] It also inhibits human polymerases, but this action is 8–600 times weaker than its actions on viral DNA polymerases. [5] It also incorporates itself into viral DNA, hence inhibiting viral DNA synthesis during reproduction. [5]

It possesses in vitro activity against the following viruses: [26]

History

Cidofovir was discovered at the Institute of Organic Chemistry and Biochemistry, Prague, by Antonín Holý, and developed by Gilead Sciences [27] and is marketed with the brand name Vistide by Gilead in the US, and by Pfizer elsewhere.

Synthesis

Cidofovir can be synthesized from a pyrimidone derivative and a protected derivative of glycidol. [28]

Cidofovir syn.png

See also

Related Research Articles

<span class="mw-page-title-main">Antiviral drug</span> Medication used to treat a viral infection

Antiviral drugs are a class of medication used for treating viral infections. Most antivirals target specific viruses, while a broad-spectrum antiviral is effective against a wide range of viruses. Antiviral drugs are a class of antimicrobials, a larger group which also includes antibiotic, antifungal and antiparasitic drugs, or antiviral drugs based on monoclonal antibodies. Most antivirals are considered relatively harmless to the host, and therefore can be used to treat infections. They should be distinguished from virucides, which are not medication but deactivate or destroy virus particles, either inside or outside the body. Natural virucides are produced by some plants such as eucalyptus and Australian tea trees.

<span class="mw-page-title-main">Aciclovir</span> Antiviral medication used against herpes, chickenpox, and shingles

Aciclovir, also known as acyclovir, is an antiviral medication. It is primarily used for the treatment of herpes simplex virus infections, chickenpox, and shingles. Other uses include prevention of cytomegalovirus infections following transplant and severe complications of Epstein–Barr virus infection. It can be taken by mouth, applied as a cream, or injected.

Reverse-transcriptase inhibitors (RTIs) are a class of antiretroviral drugs used to treat HIV infection or AIDS, and in some cases hepatitis B. RTIs inhibit activity of reverse transcriptase, a viral DNA polymerase that is required for replication of HIV and other retroviruses.

<span class="mw-page-title-main">Valaciclovir</span> Antiviral medication

Valaciclovir, also spelled valacyclovir, is an antiviral medication used to treat outbreaks of herpes simplex or herpes zoster (shingles). It is also used to prevent cytomegalovirus following a kidney transplant in high risk cases. It is taken by mouth.

<span class="mw-page-title-main">Tenofovir disoproxil</span> Antiviral drug used to treat or prevent HIV and hepatitis infections

Tenofovir disoproxil, sold under the trade name Viread among others, is a medication used to treat chronic hepatitis B and to prevent and treat HIV/AIDS. It is generally recommended for use with other antiretrovirals. It may be used for prevention of HIV/AIDS among those at high risk before exposure, and after a needlestick injury or other potential exposure. It is sold both by itself and together in combinations such as emtricitabine/tenofovir, efavirenz/emtricitabine/tenofovir, and elvitegravir/cobicistat/emtricitabine/tenofovir. It does not cure HIV/AIDS or hepatitis B. It is available by mouth as a tablet or powder.

<span class="mw-page-title-main">Azacitidine</span> Chemical compound

Azacitidine, sold under the brand name Vidaza among others, is a medication used for the treatment of myelodysplastic syndrome, myeloid leukemia, and juvenile myelomonocytic leukemia. It is a chemical analog of cytidine, a nucleoside in DNA and RNA. Azacitidine and its deoxy derivative, decitabine were first synthesized in Czechoslovakia as potential chemotherapeutic agents for cancer.

Orthopoxvirus is a genus of viruses in the family Poxviridae and subfamily Chordopoxvirinae. Vertebrates, including mammals and humans, and arthropods serve as natural hosts. There are 12 species in this genus. Diseases associated with this genus include smallpox, cowpox, horsepox, camelpox, and mpox. The most widely known member of the genus is Variola virus, which causes smallpox. It was eradicated globally by 1977, through the use of Vaccinia virus as a vaccine. The most recently described species is the Alaskapox virus, first isolated in 2015.

<span class="mw-page-title-main">Foscarnet</span> Chemical compound

Foscarnet (phosphonomethanoic acid), known by its brand name Foscavir, is an antiviral medication which is primarily used to treat viral infections involving the Herpesviridae family. It is classified as a pyrophosphate analog DNA polymerase inhibitor. Foscarnet is the conjugate base of a chemical compound with the formula HO2CPO3H2 (Trisodium phosphonoformate).

<span class="mw-page-title-main">Elvitegravir</span> Chemical compound

Elvitegravir (EVG) is an integrase inhibitor used to treat HIV infection. It was developed by the pharmaceutical company Gilead Sciences, which licensed EVG from Japan Tobacco in March 2008. The drug gained approval by the U.S. Food and Drug Administration on August 27, 2012, for use in adult patients starting HIV treatment for the first time as part of the fixed dose combination known as Stribild. On September 24, 2014, the FDA approved Elvitegravir as a single pill formulation under the trade name Vitekta. On November 5, 2015, the FDA approved the drug for use in patients affected with HIV-1 as a part of a second fixed dose combination pill known as Genvoya.

<span class="mw-page-title-main">Cobicistat</span> Chemical compound

Cobicistat, sold under the brand name Tybost, is a medication for use in the treatment of human immunodeficiency virus infection (HIV/AIDS). Its major mechanism of action is through the inhibition of human CYP3A proteins.

<span class="mw-page-title-main">Sofosbuvir</span> Chemical compound

Sofosbuvir, sold under the brand name Sovaldi among others, is a medication used to treat hepatitis C. It is taken by mouth.

<span class="mw-page-title-main">Simeprevir</span> Chemical compound

Simeprevir, sold under the brand name Olysio among others, is a medication used in combination with other medications for the treatment of hepatitis C. It is specifically used for hepatitis C genotype 1 and 4. Medications it is used with include sofosbuvir or ribavirin and peginterferon-alfa. Cure rates are in 80s to 90s percent. It may be used in those who also have HIV/AIDS. It is taken by mouth once daily for typically 12 weeks.

Ledipasvir is a drug for the treatment of hepatitis C that was developed by Gilead Sciences. After completing Phase III clinical trials, on February 10, 2014, Gilead filed for U.S. approval of a ledipasvir/sofosbuvir fixed-dose combination tablet for genotype 1 hepatitis C. The ledipasvir/sofosbuvir combination is a direct-acting antiviral agent that interferes with HCV replication and can be used to treat patients with genotypes 1a or 1b without PEG-interferon or ribavirin.

<span class="mw-page-title-main">Pritelivir</span> Chemical compound

Pritelivir is a direct-acting antiviral drug in development for the treatment of herpes simplex virus infections (HSV). This is particularly important in immune compromised patients. Pritelivir is currently in Phase III clinical development by the German biopharmaceutical company AiCuris Anti-infective Cures AG.

<span class="mw-page-title-main">Favipiravir</span> Experimental antiviral drug with potential activity against RNA viruses

Favipiravir, sold under the brand name Avigan among others, is an antiviral medication used to treat influenza in Japan. It is also being studied to treat a number of other viral infections, including SARS-CoV-2. Like the experimental antiviral drugs T-1105 and T-1106, it is a pyrazinecarboxamide derivative.

<span class="mw-page-title-main">Brincidofovir</span> Antiviral drug

Brincidofovir, sold under the brand name Tembexa, is an antiviral drug used to treat smallpox. Brincidofovir is a prodrug of cidofovir. Conjugated to a lipid, the compound is designed to release cidofovir intracellularly, allowing for higher intracellular and lower plasma concentrations of cidofovir, effectively increasing its activity against dsDNA viruses, as well as oral bioavailability.

<span class="mw-page-title-main">Ledipasvir/sofosbuvir</span> Medication used to treat hepatitis C

Ledipasvir/sofosbuvir, sold under the trade name Harvoni among others, is a medication used to treat hepatitis C. It is a fixed-dose combination of ledipasvir and sofosbuvir. Cure rates are 94% to 99% in people infected with hepatitis C virus (HCV) genotype 1. Some evidence also supports use in HCV genotype 3 and 4. It is taken daily by mouth for 8–24 weeks.

<span class="mw-page-title-main">Baloxavir marboxil</span> Antiviral medication

Baloxavir marboxil, sold under the brand name Xofluza, is an antiviral medication for treatment of influenza A and influenza B. It was approved for medical use both in Japan and in the United States in 2018, and is taken as a single dose by mouth. It may reduce the duration of flu symptoms by about a day, but is prone to selection of resistant mutants that render it ineffectual.

HSV epigenetics is the epigenetic modification of herpes simplex virus (HSV) genetic code.

<span class="mw-page-title-main">Lobucavir</span> Chemical compound

Lobucavir is an antiviral drug that shows broad-spectrum activity against herpesviruses, hepatitis B and other hepadnaviruses, HIV/AIDS and cytomegalovirus. It initially demonstrated positive results in human clinical trials against hepatitis B with minimal adverse effects but was discontinued from further development following the discovery of increased risk of cancer associated with long-term use in mice. Although this carcinogenic risk is present in other antiviral drugs, such as zidovudine and ganciclovir that have been approved for clinical use, development was halted by Bristol-Myers Squibb, its manufacturer.

References

  1. ↑ "Drug and medical device highlights 2018: Helping you maintain and improve your health". Health Canada . 14 October 2020. Retrieved 17 April 2024.
  2. ↑ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA . Retrieved 22 Oct 2023.
  3. ↑ Cundy, Kenneth C. "Clinical Pharmacokinetics of the Antiviral Nucleotide Analogues Cidofovir and Adefovir." Clinical Pharmacokinetics 36.2 (1999): 127–143.
  4. 1 2 3 4 5 "Vistide (cidofovir) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Retrieved 4 February 2014.
  5. 1 2 3 4 5 6 7 8 "Product Information VISTIDE®". TGA eBusiness Services. Gilead Sciences Pty Ltd. 3 September 2013. Retrieved 5 February 2014.
  6. ↑ Long SS, Prober CG, Fischer M (2012). Principles and Practice of Pediatric Infectious Disease. Elsevier Health Sciences. p. 1502. ISBN   978-1437727029.
  7. ↑ Chilukuri S, Rosen T (April 2003). "Management of acyclovir-resistant herpes simplex virus". Dermatologic Clinics. 21 (2): 311–320. doi:10.1016/S0733-8635(02)00093-1. PMID   12757254.
  8. ↑ Segarra-Newnham M, Vodolo KM (June 2001). "Use of cidofovir in progressive multifocal leukoencephalopathy". The Annals of Pharmacotherapy. 35 (6): 741–744. doi:10.1345/aph.10338. PMID   11408993. S2CID   32026770.[ permanent dead link ]
  9. ↑ De Gascun CF, Carr MJ (2013). "Human polyomavirus reactivation: disease pathogenesis and treatment approaches". Clinical & Developmental Immunology. 2013: 373579. doi: 10.1155/2013/373579 . PMC   3659475 . PMID   23737811.
  10. ↑ De Clercq E (July 2002). "Cidofovir in the treatment of poxvirus infections". Antiviral Research. 55 (1): 1–13. doi:10.1016/S0166-3542(02)00008-6. PMC   9533828 . PMID   12076747.
  11. ↑ Bradbury J (March 2002). "Orally available cidofovir derivative active against smallpox". Lancet. 359 (9311): 1041. doi:10.1016/S0140-6736(02)08115-1. PMID   11937193. S2CID   22903225.
  12. ↑ Magee WC, Hostetler KY, Evans DH (August 2005). "Mechanism of inhibition of vaccinia virus DNA polymerase by cidofovir diphosphate". Antimicrobial Agents and Chemotherapy. 49 (8): 3153–3162. doi:10.1128/AAC.49.8.3153-3162.2005. PMC   1196213 . PMID   16048917.
  13. ↑ Araya CE, Lew JF, Fennell RS, Neiberger RE, Dharnidharka VR (February 2006). "Intermediate-dose cidofovir without probenecid in the treatment of BK virus allograft nephropathy". Pediatric Transplantation. 10 (1): 32–37. doi:10.1111/j.1399-3046.2005.00391.x. PMID   16499584. S2CID   24131709.
  14. ↑ Broekema FI, Dikkers FG (August 2008). "Side-effects of cidofovir in the treatment of recurrent respiratory papillomatosis". European Archives of Oto-Rhino-Laryngology. 265 (8): 871–879. doi:10.1007/s00405-008-0658-0. PMC   2441494 . PMID   18458927.
  15. ↑ Soma MA, Albert DM (February 2008). "Cidofovir: to use or not to use?". Current Opinion in Otolaryngology & Head and Neck Surgery. 16 (1): 86–90. doi:10.1097/MOO.0b013e3282f43408. PMID   18197029. S2CID   22895067.
  16. ↑ "Cidofovir Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 5 February 2014.
  17. ↑ "Vistide : EPAR – Product Information" (PDF). European Medicines Agency. Gilead Sciences International Ltd. 7 November 2013. Retrieved 5 February 2014.
  18. ↑ Fernández-Morano T, del Boz J, González-Carrascosa M, Tortajada B, de Troya M (December 2011). "Topical cidofovir for viral warts in children". Journal of the European Academy of Dermatology and Venereology. 25 (12): 1487–1489. doi: 10.1111/j.1468-3083.2010.03961.x . PMID   21261749. S2CID   32295082.
  19. ↑ Kern ER (January 2003). "In vitro activity of potential anti-poxvirus agents". Antiviral Research. 57 (1–2): 35–40. doi:10.1016/s0166-3542(02)00198-5. PMC   9628899 . PMID   12615301. S2CID   23136929.
  20. ↑ Andrei G, Snoeck R (December 2010). "Cidofovir Activity against Poxvirus Infections". Viruses. 2 (12): 2803–2830. doi: 10.3390/v2122803 . PMC   3185586 . PMID   21994641.
  21. ↑ "Interim Clinical Guidance for the Treatment of Monkeypox". U.S. Centers for Disease Control and Prevention. 26 May 2022.
  22. 1 2 "Details" (PDF). www.gilead.com. Retrieved 2019-06-05.
  23. ↑ Lacy SA, Hitchcock MJ, Lee WA, Tellier P, Cundy KC (August 1998). "Effect of oral probenecid coadministration on the chronic toxicity and pharmacokinetics of intravenous cidofovir in cynomolgus monkeys". Toxicological Sciences. 44 (2): 97–106. doi: 10.1006/toxs.1998.2481 . PMID   9742650.
  24. 1 2 3 Rossi S, ed. (2013). Australian Medicines Handbook (2013 ed.). Adelaide: The Australian Medicines Handbook Unit Trust. ISBN   978-0-9805790-9-3.
  25. ↑ "Vistide (cidofovir)" (PDF) (package insert). Gilead Sciences. September 2010. Dosage and Administration: Dosage.
  26. ↑ Safrin S, Cherrington J, Jaffe HS (September 1997). "Clinical uses of cidofovir". Reviews in Medical Virology. 7 (3): 145–156. doi:10.1002/(SICI)1099-1654(199709)7:3<145::AID-RMV196>3.0.CO;2-0. PMID   10398479. S2CID   32366514.
  27. ↑ "Press Releases: Gilead". Archived from the original on 2013-02-08. Retrieved 2007-12-05.
  28. ↑ Brodfuehrer PR, Howell HG, Sapino Jr C, Vemishetti P (1994). "A practical synthesis of (S)-HPMPC". Tetrahedron Letters. 35 (20): 3243. doi:10.1016/S0040-4039(00)76875-4.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.